Retatrutide. Another year, another miracle weight loss drug with a name you can’t pronounce. Are we happy, or are we… nervous?
Let’s get one thing straight before we even start:Retatrutide is not a vibe. It is a once-weekly injectable triple hormone receptor agonist — GLP-1, GIP, and glucagon, all in one shot. The most powerful weight loss drug ever tested in clinical trials. It will probably have a fun nickname by 2027. And if the pattern holds? By 2030 somebody will be suing over something nobody saw coming in the trial.
We’re not saying that to be dramatic. We’re saying it because we’ve seen this movie.
First, Let’s Talk About What Retatrutide Actually Is
Phase 3 results dropped in December 2025 and the numbers were genuinely wild: patients on the highest dose lost an average of 71 pounds over 68 weeks. Some lost over 35% of their body weight. A handful stopped the trial early because — and this is in the actual press release — they had experienced “perceived excessive weight loss.“ The drug worked so well people had to tap out.
It’s not FDA approved yet. Eli Lilly can’t apply until Phase 3 wraps up, expected in 2026, with approval projected for 2027 at the earliest. Already people are buying whatever shady online pharmacies are calling retatrutide. FDA has sent warning letters. We’re begging: please don’t inject mystery substances from a website that looks like it hasn’t been updated since 2011.
Someone stopped a clinical trial because the drug worked TOO well. Re-read that sentence.”
Now Let’s Talk About Ozempic. Because We Have to.
Ozempic, semaglutide, became a whole cultural moment around 2022. Celebrities who denied taking it, then celebrities who admitted it, then the shortages that left actual diabetics who actually needed it unable to get their prescription because every influencer’s wellness-adjacent friend had discovered a new personality. You remember.
And then the lawsuits started. As of April 2026, there are over 3,500 pending lawsuits against Novo Nordisk and Eli Lilly across two federal multidistrict litigations. The injuries being claimed include gastroparesis (stomach paralysis, basically), vision loss from a rare condition called NAION (which a Harvard doctor described as “a stroke of the optic nerve”), pancreatitis, kidney damage, and thyroid cancer concerns that researchers are still investigating.
The Ozempic warning label has been updated four times since it was approved. Gallbladder disease added in 2022. Intestinal blockages in 2023. Pulmonary aspiration risks for surgery patients in November 2024. Severe pancreatitis and kidney injuries in January 2025. The WHO issued a warning in June 2025 about the eye condition risk. The European Medicines Agency followed. And the drug is still the most prescribed medication in its class.
“The Ozempic warning label has been updated four times since approval. Four.”
The Part Nobody’s Saying at Volume
Pharma companies don’t make billions on drugs that are taken for three months. Ozempic, Wegovy, Zepbound, these are maintenance medications. You stop taking them, the weight comes back. The business model is monthly refills, forever, at prices that start around $900 a month without insurance. Eli Lilly’s obesity drug revenue approximately hit $5.4 billion by Q4 2024. Novo Nordisk became the most valuable company in Europe on the back of semaglutide sales. Nobody in that boardroom is rooting for a one-and-done cure.
And before them? The fasting teas. The detox cleanses. The slimming patches. The ‘metabolism boosting’ supplements. The weight loss industry has been extracting money from people’s insecurities for decades, and each chapter gets more medically legitimate and more expensive than the last. That’s not an accident.
We’re not saying retatrutide doesn’t work. It clearly does. We’re not saying nobody should take GLP-1 drugs. For some people, they are genuinely life-changing. What we are saying is: the speed at which these pharmas are bringing the next-biggest-thing to market, while the lawsuits over the current things are still being filed, is a pattern worth noticing.
The class actions always come later. Vioxx. Fen-Phen. Paxil. Bextra. The pharmaceutical graveyard of drugs that were miraculous until they weren’t is a very long list. Retatrutide might be different. It might be safe forever. But the people telling you that with the most confidence are also the people whose quarterly earnings depend on you believing it.
We just wanted to say that part out loud. Now go talk to your actual doctor.